Sexually transmitted infections have been increasing among men who have sex with men. Doxycycline prophylaxis for syphilis and chlamydia has been effective in initial trials. Future research should focus on populations with high incidence/morbidity, dose and regimen, and antimicrobial resistance.
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Background
Bacterial sexually transmitted infections (STI) have been steadily increasing in gay, bisexual, and other men who have sex with men (MSM) over the past two decades. [1] [2] [3] [4] . While that trend started prior to the introduction of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) in 2012, [1, 3] HIV PrEP has been associated with increases in sexual contacts and decreases in condom use with an resultant acceleration in the increase of bacterial STIs like gonorrhea, syphilis and chlamydia. [5] [6] [7] [8] However, the increasing adoption of HIV PrEP [8] has shown that biomedical interventions for STI prevention can be effective, safe, and highly acceptable.
This state-of-the-art review was conducted to examine the current state of research, knowledge gaps, and challenges around the use of doxycycline prophylaxis to prevent syphilis, caused by Treponema pallidum (TP), and other bacterial STIs such as Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). International public health and clinical experts from academia, government, and community-based organizations met on March 3, 2019 , in Seattle, Washington to frame the initial inquiry which was then supplemented by focused literature searches to address specific questions of interest. Findings are summarized using the Grading of Recommendations, Assessment, Development and Evaluations framework specifically focusing on the quality of evidence and benefits versus harms. [9] Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz866/5557867 by guest on 05 September 2019
Current evidence on doxycycline prophylaxis
Doxycycline is a moderate-spectrum second-generation tetracycline that is generally well tolerated. [10] It is rapidly and almost completely absorbed after oral administration. [10] First introduced commercially in the 1960s, doxycycline has been used by millions to manage acne and as primary prophylaxis for scrub typhus, [11] leptospirosis, [12] malaria, [13] and Lyme disease. [14] There are anecdotal reports of doxycycline used for syphilis prophylaxis among U.S. and Australian military personnel during the Vietnam War. Doxycycline is a first-line agent for treatment of chlamydia and an alternative regimen for syphilis. [10, 15] Several studies examined doxycycline prophylaxis for STI prevention. (Table 1) In a small open-label pilot study, 30 HIV-infected MSM with prior syphilis were randomized 1:1 to daily doxycycline 100 mg as pre-exposure prophylaxis (Doxy PrEP) for 48 weeks versus a financial incentive-based behavioral intervention. [16] There was a 73% reduction (p = .02) in syphilis, GC, or CT in the Doxy PrEP group compared to the control group. Most intervention-arm participants maintained blood doxycycline levels >1 μg/mL. Reported sexual behaviors were similar in both groups.
An open-label extension of the French national HIV research agency (ANRS) IPERGAY
HIV prevention study continued participant access to HIV PrEP and examined doxycycline post-exposure prophylaxis (Doxy PEP) in HIV-uninfected MSM and transgender women. [17] Participants (n=232) were randomly assigned 1:1 to the intervention, doxycycline 200 mg within 24-72 hours of condomless sexual encounters up to three times per week, or to no prophylaxis. Those taking Doxy PEP had lower STI incidence (hazard ratio = 0.57, p = .014). CT and syphilis diagnoses were significantly lower in the intervention arm with a relative reduction of 70-73% in the intention-to-treat analysis. NG diagnoses did not differ except for fewer urethral cases in those using Doxy PEP. Four of nine NG-positive cultures, all from the control arm, had high-level tetracycline resistance consistent with the French background rate. [10] Eighty-two percent (n=31) of participants with NG detected by nucleic acid amplification testing had genotypic markers of tetracycline resistance; there was no difference between study arms (p = .4). All CT culture isolates (n=5) were doxycycline-susceptible. Adherence was high in the Doxy PEP arm; 63% had doxycycline detected in at least one plasma specimen. Twenty-nine (21.5%) Doxy PEP patients discontinued doxycycline, eight for gastrointestinal side effects. Sexual behaviors did not generally differ between the two groups.
While not direct clinical evidence, a modeling study examining the impact of Doxy PrEP on syphilis among Australian MSM estimated that if 50% of MSM used Doxy PrEP and it was 70% effective, syphilis would decrease by 50% after 12 months and 85% after 10 years. [18] The authors predicted a similar effect if only 50% of men with > 20 partners in six months were taking doxycycline. contact, up to daily use, versus standard of care with 12 months follow-up. All positive NG cultures will undergo tetracycline susceptibility testing. Specimens from patients diagnosed with syphilis or CT will undergo molecular tetracycline resistance evaluation using a novel CRISPR/Cas9 targeted sequencing technique. [20] That will provide a broad reaching, rapid throughput methodology for assessing tetracycline and other antimicrobial resistance genes. Participants will have nasopharyngeal swabs cultured to assess for tetracycline susceptibility in Staphylococcus aureus and Neisseria spp., and rectal swabs and stool samples for metagenomic tests to determine predominant species, species diversity, and changes in the presence of tetracycline resistance genes over time.
Knowledge gaps and challenges
While the studies described above help address some of the knowledge gaps around Doxy PEP/PrEP, there remain multiple areas for further research particularly around efficacy, and potential benefits and harms.
Quality of the evidence
Efficacy
Studies on Doxy PEP/PrEP use two doxycycline dose/regimen options: 100mg daily [16] or 200 mg single dose post-condomless sex event. [17] Investigators selected those regimens from experience with doxycycline prophylaxis in other infectious diseases [12, 14] and the minimum inhibitory concentration (MIC) of TP. [21] The efficacy of doxycycline for pre-or post-exposure prophylaxis has yet to be definitively determined.
While the two randomized controlled trials (RCT) conducted to date had similar levels of efficacy (approximately 70%), the estimated effect sizes were imprecise because of modest sample sizes. [16, 17, 22] Additionally, it is unknown which specific sex acts were protected. Studies underway will lead to more precise measures of overall efficacy and efficacy for specific sexual behaviors. Those measures are important to inform clinical decision-making, cost-effectiveness analyses, community education, and patient counseling.
Population of focus
Public health experts have long promoted controlling STIs in a core population of individuals with a high number of sexual contacts as an approach to reduce STIs in the general population. [23, 24] Modeling based on Australian parameters [18] Most serious adverse effects resolve with discontinuation of doxycycline. [25] Despite the known side effects, in clinical trials discontinuation due to side effects has been uncommon. [13, 16, 17, 26] Clinicians routinely prescribe low doses (40-100 mg daily) of doxycycline for weeks to months for acne and rosacea [25] and months to years for malaria prophylaxis. [13] Multiple studies on side effects among patients using doxycycline for malaria prophylaxis have been contradictory or insufficient to draw clear conclusions. [13] Researchers have studied prolonged doxycycline use ( 
Antimicrobial resistance
Concern around antimicrobial resistance has been raised by some clinicians and public health organizations, along with a call for more research in this area. [31] In the U.S., 23 .1% of NG isolates tested in 2017 were resistant to tetracycline [1] ; NG resistance to tetracycline is higher in some parts of Europe (France: 45%; England: 49%). [10, 32] Additionally, gonococcal antimicrobial resistance is frequently higher among MSM, [1, 32] the population most likely to use Doxy PEP/PrEP. However. given the existing high rates of tetracycline resistance in NG and the fact that doxycycline is not recommended for treatment, another perspective may be that the additional contribution of prophylactic use to NG resistance in this context is negligible.
There are no established standards for identifying or measuring doxycycline resistance in NG, CT, or TP via culture or molecular techniques, although investigators have developed methods for research purposes and most clinicians apply tetracycline susceptibility data for NG to doxycycline. [33] [34] [35] Treatment failure in CT has been reported in 5-23% of persons, [36] although these studies did not test for resistance and the causes of treatment failure are unclear.
Treatment failure in patients with CT has been associated with a range of in vitro doxycycline MICs of >0.125 μg/mL to >4.0 μg/mL, [33, 37] however there is not a strict correlation between treatment failure and tested MIC [33] so the clinical relevance of these findings are unclear. Several small population-level studies in communities with high background doxycycline use or subsequent to mass-treatment programs for trachoma did not find evidence of doxycycline resistance in CT. [36] Two studies have evaluated tetracycline resistance in TP. In China, molecular typing of serum from 438 case-patients [34] with syphilis found no evidence of a mutation in the 16S rRNA gene that is associated with tetracycline resistance in other bacterial species.
A similar study of 53 case-patients in Italy [38] also did not identify any doxycycline resistance mutations. Complete genome sequencing of TP [39] has not found genetic elements associated with gene transfer mechanisms. That suggests that TP is less likely than other bacteria to develop plasmid-mediated antimicrobial resistance.
However, macrolide resistance in TP has been documented to occur due to a single point mutation [40] suggesting the potential for tetracycline resistance. [41] Antimicrobial resistance in Mycoplasma genitalium (MG), a frequent cause of nongonococcal urethritis in men, is also a growing concern.[42, 43] Even though tetracyclines have low efficacy against MG [15] , doxycycline is a recommended alternative regimen [15] because of emerging resistance to first-line treatments. In a substudy of the ANRS IPERGAY doxycycline extension, 11% of the 210 participants tested positive for MG at baseline and eleven participants acquired MG during the study. [43] Azithromycin and fluoroquinolone resistance was identified in 70% and 15% respectively of tested specimens. [43] Broad doxycycline use in populations with high prevalence rates of MG could decrease treatment options for that bacteria. MG prevalence and antibiotic susceptibilities should be examined in future studies.
Finally, Doxy PEP/PrEP could contribute to development of doxycycline resistance in commensal organisms, including those with the potential to transmit resistance. Studies of military deployed overseas taking doxycycline for malaria prophylaxis have found conflicting data on the impact of doxycycline prophylaxis on antimicrobial resistance in oropharyngeal and intestinal commensal organisms. [44] [45] [46] Further study is needed.
While it is possible to evaluate the impact of doxycycline on oral and rectal flora by examining the microbiome and resistome in these areas, there are no standard guidelines for interpreting findings.
Community acceptability and perceptions
Multiple surveys have demonstrated that doxycycline prophylaxis is acceptable to MSM.
In an online survey of 2,095 Australian MSM, 53% indicated they would be likely to take doxycycline to prevent syphilis and 76% indicated they would take doxycycline to reduce syphilis in the community. [ Researchers and study participants have expressed concern about the potential for Effective educational campaigns, designed using evidence from ongoing and future studies, will be critical to address those concerns.
Risk compensation
Investigators have documented decreased condom use among MSM using HIV 
Risk/benefit and cost-effectiveness
While the benefits of HIV PREP as a way to prevent a life threatening infection are clear, the risk-balance of STI prevention may be more uncertain. As Golden and
Handsfield suggest, [22] a key issue to consider is which benefits of Doxy PEP/PrEP are most important to prioritize. While STI treatment has significant personal and financial costs, and STIs can cause serious sequelae in men (e.g., blindness and hearing loss due to syphilis), much of the direct STI morbidity is in women (infertility and adverse pregnancy outcomes). Primarily using Doxy PEP/PrEP in MSM, a population at high risk for bacterial STIs, might have relatively limited impact on reproductive health outcomes at the population level. The question of which benefits to focus on will also directly impact the cost-effectiveness of Doxy PEP/PrEP as the number of people who would need to receive treatment to avert a negative outcome will vary substantially depending on the outcome selected. [22] 
Conclusions
Based on our review of the current evidence and studies underway, doxycycline prophylaxis for bacterial STIs shows promise. However, there are several research priorities that need to be addressed before it be adopted broadly. (Figure) In 
